These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 14599658)

  • 1. Recent advances in understanding the pathogenesis of polyglutamine diseases: involvement of molecular chaperones and ubiquitin-proteasome pathway.
    Jana NR; Nukina N
    J Chem Neuroanat; 2003 Oct; 26(2):95-101. PubMed ID: 14599658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranuclear ataxin1 inclusions contain both fast- and slow-exchanging components.
    Stenoien DL; Mielke M; Mancini MA
    Nat Cell Biol; 2002 Oct; 4(10):806-10. PubMed ID: 12360291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promyelocytic leukemia protein is redistributed during the formation of intranuclear inclusions independent of polyglutamine expansion: an immunohistochemical study on Marinesco bodies.
    Kumada S; Uchihara T; Hayashi M; Nakamura A; Kikuchi E; Mizutani T; Oda M
    J Neuropathol Exp Neurol; 2002 Nov; 61(11):984-91. PubMed ID: 12430715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein aggregation and the ubiquitin proteasome pathway: gaining the UPPer hand on neurodegeneration.
    Berke SJ; Paulson HL
    Curr Opin Genet Dev; 2003 Jun; 13(3):253-61. PubMed ID: 12787787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy.
    Abu-Baker A; Messaed C; Laganiere J; Gaspar C; Brais B; Rouleau GA
    Hum Mol Genet; 2003 Oct; 12(20):2609-23. PubMed ID: 12944420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity.
    Sakahira H; Breuer P; Hayer-Hartl MK; Hartl FU
    Proc Natl Acad Sci U S A; 2002 Dec; 99 Suppl 4(Suppl 4):16412-8. PubMed ID: 12189209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of impaired proteasomal function in a cellular model of polyglutamine diseases.
    Jana NR; Nukina N
    Methods Mol Biol; 2004; 277():287-92. PubMed ID: 15201463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
    Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
    Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo.
    Hernández F; Díaz-Hernández M; Avila J; Lucas JJ
    Trends Neurosci; 2004 Feb; 27(2):66-9. PubMed ID: 15106649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function.
    Tsai YC; Fishman PS; Thakor NV; Oyler GA
    J Biol Chem; 2003 Jun; 278(24):22044-55. PubMed ID: 12676955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inefficient degradation of truncated polyglutamine proteins by the proteasome.
    Holmberg CI; Staniszewski KE; Mensah KN; Matouschek A; Morimoto RI
    EMBO J; 2004 Oct; 23(21):4307-18. PubMed ID: 15470501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates.
    Donaldson KM; Li W; Ching KA; Batalov S; Tsai CC; Joazeiro CA
    Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8892-7. PubMed ID: 12857950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein surveillance machinery in brains with spinocerebellar ataxia type 3: redistribution and differential recruitment of 26S proteasome subunits and chaperones to neuronal intranuclear inclusions.
    Schmidt T; Lindenberg KS; Krebs A; Schöls L; Laccone F; Herms J; Rechsteiner M; Riess O; Landwehrmeyer GB
    Ann Neurol; 2002 Mar; 51(3):302-10. PubMed ID: 11891825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role for the ubiquitin-proteasome system in Parkinson's disease and other neurodegenerative brain amyloidoses.
    Moore DJ; Dawson VL; Dawson TM
    Neuromolecular Med; 2003; 4(1-2):95-108. PubMed ID: 14528055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single amino acid substitution in a proteasome subunit triggers aggregation of ubiquitinated proteins in stressed neuronal cells.
    Li Z; Arnaud L; Rockwell P; Figueiredo-Pereira ME
    J Neurochem; 2004 Jul; 90(1):19-28. PubMed ID: 15198663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurodegeneration: linking ubiquitin/proteasome pathway impairment with inflammation.
    Li Z; Jansen M; Pierre SR; Figueiredo-Pereira ME
    Int J Biochem Cell Biol; 2003 May; 35(5):547-52. PubMed ID: 12672447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome degrades soluble expanded polyglutamine completely and efficiently.
    Michalik A; Van Broeckhoven C
    Neurobiol Dis; 2004 Jun; 16(1):202-11. PubMed ID: 15207277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transferring substrates to the 26S proteasome.
    Hartmann-Petersen R; Seeger M; Gordon C
    Trends Biochem Sci; 2003 Jan; 28(1):26-31. PubMed ID: 12517449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyglutamine-mediated neurodegeneration: use of chaperones as prevention strategy.
    Paul S
    Biochemistry (Mosc); 2007 Apr; 72(4):359-66. PubMed ID: 17511600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring the ubiquitin/proteasome system in conformational diseases.
    Lindsten K; Dantuma NP
    Ageing Res Rev; 2003 Oct; 2(4):433-49. PubMed ID: 14522245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.